James Thomson's isolation of human embryonic stem cells in 1998 and his parallel development of human iPS cells in 2007 established foundational platforms for regenerative medicine. Thomson's initial derivation of human embryonic stem cells from blastocysts created the first renewable source of pluripotent human cells available for research and development, catalysing the field itself. His later work on human iPS reprogramming, concurrent with Yamanaka's but using a different set of transcription factors, validated that multiple reprogramming strategies could achieve pluripotency and strengthened the scientific foundation. These parallel breakthroughs—embryonic and induced—provided researchers with complementary tools: ESCs for developmental biology and benchmarking, iPS cells for disease modelling and potentially autologous therapy. Thomson's laboratory also pioneered directed differentiation protocols, demonstrating reproducible generation of specific cell types from pluripotent precursors. Today, clinical applications largely favour iPS-derived products over ESCs, but Thomson's original characterisation of human ESC properties remains the reference standard. His contributions span cell derivation, characterisation, differentiation, and translational strategy; collectively, they seeded the modern landscape of cell therapy development and clinical trials across multiple disease areas.
Most clinical uses of stem cells remain investigational — check the evidence and approval status for your condition before acting on any clinic's claims.
Sources & profiles
← All pioneers · Conditions compared →